GlaxoSmithKline News and Research

RSS

AltheRx purchases all assets related to Solabegron from GlaxoSmithKline

AltheRx Inc., a privately-held clinical development company, announced today that it has purchased all assets related to Solabegron from GlaxoSmithKline. Solabegron is a highly selective and potent beta3-adrenoceptor agonist that has demonstrated positive results in Phase II clinical programs for the treatment of Overactive Bladder in women and Irritable Bowel Syndrome.

25 Mar 2011

House bill proposes immunity for negligent drug manufacturers

Rep. Johnathan Rhyne, Republican Chairman of the NC House Select Committee on Tort Reform, today launched an assault on patients rights, adding provisions to favor insurance companies and drug manufacturers to a controversial Senate bill.

24 Mar 2011

Decision Resources: 68% of gastroenterologists select Remicade for Crohn's treatment

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than two-thirds of surveyed gastroenterologists selected Centocor Ortho Biotech/Merck & Co./Mitsubishi Tanabe's Remicade as the most efficacious therapy for Crohn's disease, when compared to other currently available agents.

24 Mar 2011

Cilag, POZEN enter license agreement to develop and commercialize MT 400

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has entered into a license agreement with Cilag GmbH International, a division of Johnson & Johnson, for the development and commercialization of MT 400 in Brazil, Colombia, Ecuador and Peru.

23 Mar 2011

POZEN files motion for Treximet patent litigation against Par

POZEN Inc., a pharmaceutical company committed to transforming medicines that transform lives, today announced that it has filed a motion for a preliminary injunction seeking to prevent Par Pharmaceuticals, Inc. from launching a generic version of Treximet.

23 Mar 2011

Publicis Groupe agrees to acquire majority stake in India-based Watermelon

Publicis Groupe announced today that it has agreed to acquire a majority stake in a leading healthcare advertising agency in Mumbai, India-Watermelon Healthcare Communications Private Limited.

22 Mar 2011

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

A study published online in this week's Nature Genetics demonstrates that tiny Locked Nucleic Acid (LNA)-based compounds developed by Santaris Pharma A/S can inhibit entire disease-associated microRNA families. This provides a potential new approach for treating a variety of diseases including cancer, viral infections, cardiovascular and muscle diseases.

21 Mar 2011

New lozenge clinical trial for dry mouth treatment

A clinical trial using an all-natural lozenge to treat dry mouth, a condition that impacts 40 percent of American adults, is under way at Georgia Health Sciences University College of Dental Medicine.

17 Mar 2011

Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today the dosing of the first subject in a Phase 2 study with an experimental oral parathyroid hormone analog for the treatment of osteoporosis in postmenopausal women.

16 Mar 2011

$HIV infection and increased fracture risk: Study$

HIV infection and increased fracture risk: Study

According to a latest study, adults between ages 25 and 54 infected with HIV, are at increased risk for bone fractures compared to the general population. Until now it was known that low bone mineral density was common in people with HIV, but no concrete proof existed.

14 Mar 2011

Alzheimer's vaccine - First evidence for efficacy

AFFiRiS' Alzheimer's vaccine candidate AD02 showed indicative evidence for potential efficacy in a phase I clinical trial. This was demonstrated by the analysis of the data from secondary clinical study endpoints.

12 Mar 2011

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.

11 Mar 2011

Scientific advances at Scripps Research lay foundation for new lupus drug Benlysta

Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.

11 Mar 2011

GSK announces new NovaMin-containing dental formulation for sensitive teeth

This year, for the first time, millions of Americans will be protecting their sensitive teeth with NovaMin in everyday dental products. Co-inventor Gary Hack, DDS, couldn't be happier.

11 Mar 2011

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has approved BENLYSTA® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

10 Mar 2011

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

The U.S. Food and Drug Administration today approved Benlysta to treat patients with active, autoantibody-positive lupus who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.

9 Mar 2011

New clinical trial to assess antiretroviral treatment in HIV-infected individuals based on CD4 counts

A major new clinical trial seeks to determine whether HIV-infected asymptomatic individuals have less risk of developing AIDS or other serious illness if they begin taking antiretrovirals sooner rather than later, based on their level of CD4+ T-cells.

8 Mar 2011

New Lupus drug marching towards approval

A new drug for lupus from the Human Genome Sciences Inc is all set to get clearance in the US this week. If all goes through, this drug will offer patients the first approved treatment option in a half-century, setting the manufacturer up for huge sales.

7 Mar 2011

Joslin launches initiative for primary care physicians to improve diabetes care

Joslin Diabetes Center has launched a groundbreaking initiative for primary care physicians to improve diabetes care.

3 Mar 2011

Meda launches Medivir's cold sore treatment Xerese in the U.S.

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the Company's commercialization partner, Meda AB, has launched Medivir's unique cold sore treatment Xerese in the United States.

1 Mar 2011

GlaxoSmithKline News and Research

AltheRx purchases all assets related to Solabegron from GlaxoSmithKline

House bill proposes immunity for negligent drug manufacturers

Decision Resources: 68% of gastroenterologists select Remicade for Crohn's treatment

Cilag, POZEN enter license agreement to develop and commercialize MT 400

POZEN files motion for Treximet patent litigation against Par

Publicis Groupe agrees to acquire majority stake in India-based Watermelon

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

New lozenge clinical trial for dry mouth treatment

Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis

HIV infection and increased fracture risk: Study

Alzheimer's vaccine - First evidence for efficacy

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Scientific advances at Scripps Research lay foundation for new lupus drug Benlysta

GSK announces new NovaMin-containing dental formulation for sensitive teeth

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

New clinical trial to assess antiretroviral treatment in HIV-infected individuals based on CD4 counts

New Lupus drug marching towards approval

Joslin launches initiative for primary care physicians to improve diabetes care

Meda launches Medivir's cold sore treatment Xerese in the U.S.

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News